Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Reviva Pharmaceuticals Holdings Inc.
RVPH | US
1.50
USD0.08
5.63%
RVPH | US
About Reviva Pharmaceuticals Holdings Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.50
Open
1.43
High
1.54
Low
1.35
Reviva Pharmaceuticals Holdings Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system respiratory cardiovascular metabolic and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063) which is in Phase III clinical trials for the treatment of schizophrenia as well as completed Phase I clinical trials to treat bipolar disorder major depressive disorder attention"deficit/hyperactivity disorder behavioral and psychotic symptoms of dementia or Alzheimer's disease Parkinson's disease psychosis attention deficit hyperactivity disorder pulmonary arterial hypertension and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino California."
View LessRVPH | US
Risk
77.3
Sharpe
-0.58
Luna's Score
45/100
Recommendation
Sell
Luna says (RVPH | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
78.9%1 month
77.3%3 months
144.9%6 months
124.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
8.35
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-6.00
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-10.10M
MarketCap
49.64M
MarketCap(USD)
49.64M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.80K
Short ratio
13.36
Short perc.
22.97
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.50
Range1M
0.50
Range3M
0.97
Volumes: Market Activity
Rel. volume
2.81
Price X volume
1.13M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.00 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 8.35 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 144.87 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 49.64M | 3.66B | Emerging |
